Subcutaneous (SC) Keytruda has completed ... drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such ...

Halozyme Therapeutics, Inc. (Halozyme), a biotechnology company that pioneered the use of human hyaluronidase for subcutaneous drug delivery, today filed a patent infringement lawsuit against Merck ...

Serkan Oray from UCB shares why the autoinjector pen format is booming, the importance of a patient-centric design, and how ...

Halozyme announces US FDA approval of argenx's Vyvgart Hytrulo prefilled syringe co-formulated with ENHANZE for self-injection for gMG and CIDP: San Diego Monday, April 14, 2025, ...

The global intradermal injection market size is expected to surpass an impressive valuation of USD 3,878 Million in 2022 and is projected to exhibit a compound annual growth rate (CAGR) of 10.8% from ...

Viking Therapeutics Inc (VKTX) reports significant progress in clinical trials and maintains a strong cash position despite ...

Q1 2025 Management View CEO Brian Lian highlighted the company's progress in advancing its VK2735 obesity program, with Phase ...

Serkan Oray from UCB shares why the autoinjector pen format is booming, the importance of a patient-centric design, and how to get a design concept off the ground.

Chief executive Chris Viehbacher said on Biogen's results call that a plan to extend the use of the subcutaneous injector into the induction phase of treatment could be a "game changer." ...

Asim Rana, Truist Securities: Asked about the timing of Phase 2 oral readout and the introduction of the auto-injector in Phase ... Phase 3 trials for the VK2735 subcutaneous program on track ...